Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | HMPL-689 |
Trade Name | |
Synonyms | HMPL689|HMPL 689|Amdizalisib |
Drug Descriptions |
HMPL-689 is a specific inhibitor of PIK3CD, which blocks downstream signaling and B-cell activation, potentially resulting in increased anti-tumor activity (Cancer Res 2022;82(12_Suppl):Abstract nr 5454). |
DrugClasses | PIK3CD inhibitor 27 |
CAS Registry Number | NA |
NCIT ID | C148532 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
HMPL-689 | HMPL-689 | 0 | 1 |